Table 3 Overall survival time and clinicopathologic factors between high-risk group and low-risk group in TCGA database
Clinical information | High-risk group | Low-risk group |
|---|---|---|
Total cases | 239(50%) | 239(50%) |
Survival status | ||
 Alive | 131(55%) | 159(67%) |
 Dead | 108(45%) | 80(33%) |
Overall survival time | ||
  < 1 year | 73(31%) | 42(17.5%) |
 1–5 years | 134(56%) | 152(63.5%) |
  > 5 years | 32(13%) | 45(19%) |
Age | ||
  < 65 | 80(33%) | 93(36%) |
  ≥ 65 | 159(67%) | 166(64%) |
Gender | ||
 Male | 68(28%) | 55(23%) |
 Female | 171(72%) | 184(77%) |
Stage | ||
 StageI | 121(51%) | 113(47%) |
 StageII | 72(30%) | 79(33%) |
 StageIII | 40(17%) | 43(18%) |
 StageIV | 6(2%) | 4(2%) |
Tumor | ||
 T1 | 63(26%) | 51(21%) |
 T2 | 131(55%) | 145(61%) |
 T3 | 31(13%) | 35(15%) |
 T4 | 14(6%) | 8(3%) |
Node | ||
 N0 | 152(64%) | 151(63%) |
 N1 | 63(26%) | 63(26%) |
 N2 | 20(8%) | 19(8%) |
 N3 | 4(2%) | 6(3%) |
Metastasis | ||
 M0 | 197(82%) | 192(80%) |
 M1 | 42(18%) | 47(20%) |